
**Armani 2017** Armani S, Ting L, Sauter N, et al. Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults. Clin Drug Investig. 2017;37(5):465-472. doi:10.1007/s40261-017-0497-0

**Benet 2011** Benet LZ, Broccatelli F, Oprea TI. BDDCS applied to over 900 drugs. AAPS J. 2011;13(4):519-547. doi:10.1208/s12248-011-9290-9

**Berezhkovskiy 2004** 1. Berezhkovskiy LM. Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. J Pharm Sci. 2004;93(6):1628-1640. doi:10.1002/jps.20073

**Brown 2007** Brown HS, Griffin M, Houston JB. Evaluation of cryopreserved human hepatocytes as an alternative in vitro system to microsomes for the prediction of metabolic clearance. Drug Metab Dispos. 2007;35(2):293-301. doi:10.1124/dmd.106.011569

**Caudle 2017** Caudle KE, Sangkuhl K, Whirl-Carrillo M, et al. Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch  Pharmacogenetics Working Group. Clin Transl Sci. 2020;13(1):116-124. doi:10.1111/cts.12692

**Capon 1996** Capon DA, Bochner F, Kerry N, Mikus G, Danz C, Somogyi AA. The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans. Clin Pharmacol Ther. 1996;60(3):295-307. doi:10.1016/S0009-9236(96)90056-9

**Duedahl 2004** Duedahl TH, Dirks J, Petersen KB, Romsing J, Larsen NE, Dahl JB. Intravenous dextromethorphan to human volunteers: relationship between pharmacokinetics and anti-hyperalgesic effect. Pain. 2005;113(3):360-368. doi:10.1016/j.pain.2004.11.015

**Dumond 2010** Dumond JB, Vourvahis M, Rezk NL, et al. A phenotype-genotype approach to predicting CYP450 and P-glycoprotein drug interactions with the mixed inhibitor/inducer tipranavir/ritonavir. Clin Pharmacol Ther. 2010;87(6):735-742. doi:10.1038/clpt.2009.253

**Edwards 2017** Edwards JE, Eliot L, Parkinson A, Karan S, MacConell L. Assessment of Pharmacokinetic Interactions Between Obeticholic Acid and Caffeine, Midazolam, Warfarin, Dextromethorphan, Omeprazole, Rosuvastatin, and Digoxin in  Phase 1 Studies in Healthy Subjects. Adv Ther. 2017;34(9):2120-2138. doi:10.1007/s12325-017-0601-0

**Ermer 2015** Ermer J, Corcoran M, Martin P. Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study. Drugs R D. 2015;15(2):175-185. doi:10.1007/s40268-015-0090-z

**Feld 2013** Feld R, Woo MM, Leighl N, et al. A clinical investigation of inhibitory effect of panobinostat on CYP2D6 substrate in patients with advanced cancer. Cancer Chemother Pharmacol. 2013;72(4):747-755. doi:10.1007/s00280-013-2237-3

**Gazzaz 2018** Gazzaz M, Kinzig M, Schaeffeler E, et al. Drinking Ethanol Has Few Acute Effects on CYP2C9, CYP2C19, NAT2, and P-Glycoprotein Activities but Somewhat Inhibits CYP1A2, CYP2D6, and Intestinal  CYP3A: So What? Clin Pharmacol Ther. 2018;104(6):1249-1259. doi:10.1002/cpt.1083

**Gorski 2004** Gorski JC, Huang SM, Pinto A, et al. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther. 2004;75(1):89-100. doi:10.1016/j.clpt.2003.09.013

**Frank 2009** Frank, D. Bewertung von pharmakokinetischen Parametern zur Phänotypisierung des menschlichen Cytochrom P450 Enzyms CYP2D6 mittels Dextromethorphan PhD thesis (Rheinische Friedrich-Wilhelms-Universität Bonn, 2009).

**Kakuda 2014** Kakuda TN, Van Solingen-Ristea RM, Onkelinx J, et al. The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects. J Clin Pharmacol. 2014;54(4):422-431. doi:10.1002/jcph.214

**Kazmi 2013** Kazmi F, Hensley T, Pope C, et al. Lysosomal sequestration (trapping) of lipophilic amine (cationic amphiphilic) drugs in immortalized human hepatocytes (Fa2N-4 cells). Drug Metab Dispos. 2013;41(4):897-905. doi:10.1124/dmd.112.050054

**Khalilieh 2018** Khalilieh S, Hussain A, Montgomery D, et al. Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to  severe psoriasis. Br J Clin Pharmacol. 2018;84(10):2292-2302. doi:10.1111/bcp.13670

**Kim 2019** Kim S, Chen J, Cheng T, et al. PubChem 2019 update: improved access to chemical data. Nucleic Acids Res. 2019;47(D1):D1102-D1109. doi:10.1093/nar/gky1033

**Kuepfer 2016** Kuepfer L, Niederalt C, Wendl T, Schlender JF, Willmann S, Lippert J, Block M, Eissing T, Teutonico D. Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model.CPT Pharmacometrics Syst Pharmacol. 2016 Oct;5(10):516-531. doi: 10.1002/psp4.12134. Epub 2016 Oct 19. 	

**Lutz 2012** Lutz JD, Isoherranen N. Prediction of relative in vivo metabolite exposure from in vitro data using two model drugs: dextromethorphan and omeprazole. Drug Metab Dispos. 2012;40(1):159-168. doi:10.1124/dmd.111.042200

**Nakashima 2007** Nakashima D, Takama H, Ogasawara Y, et al. Effect of cinacalcet hydrochloride, a new calcimimetic agent, on the pharmacokinetics of dextromethorphan: in vitro and clinical studies. J Clin Pharmacol. 2007;47(10):1311-1319. doi:10.1177/0091270007304103

**Nishimura 2013** Nishimura M, Yaguti H, Yoshitsugu H, Naito S, Satoh T. Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi. 2003;123(5):369-375. doi:10.1248/yakushi.123.369

**Nyunt 2008** Nyunt MM, Becker S, MacFarland RT, et al. Pharmacokinetic effect of AMD070, an Oral CXCR4 antagonist, on CYP3A4 and CYP2D6 substrates midazolam and dextromethorphan in healthy volunteers. J Acquir Immune Defic Syndr. 2008;47(5):559-565. doi:10.1097/QAI.0b013e3181627566

**Patent US9370513B2** LLC, A. B. I. US9370513B2 - Compositions and methods for increasing the metabolic lifetime of
dextromethorphan and related pharmacodynamic effects 2016. https://patents.google.com/patent/US9370513B2/en

**PK-Sim Ontogeny Database Version 7.3** ([https://github.com/Open-Systems-Pharmacology/OSPSuite.Documentation/blob/38cf71b384cfc25cfa0ce4d2f3addfd32757e13b/PK-Sim%20Ontogeny%20Database%20Version%207.3.pdf](https://github.com/Open-Systems-Pharmacology/OSPSuite.Documentation/blob/38cf71b384cfc25cfa0ce4d2f3addfd32757e13b/PK-Sim%20Ontogeny%20Database%20Version%207.3.pdf))	

**Qiu 2016** Qiu F, Liu S, Miao P, et al. Effects of the Chinese herbal formula “Zuojin Pill” on the pharmacokinetics of dextromethorphan in healthy Chinese volunteers with CYP2D6*10 genotype. Eur J Clin Pharmacol. 2016;72(6):689-695. doi:10.1007/s00228-016-2048-7

**Rüdesheim 2020** Rüdesheim S, Wojtyniak JG, Selzer D, et al. Physiologically Based Pharmacokinetic Modeling of Metoprolol Enantiomers and α-Hydroxymetoprolol to Describe CYP2D6 Drug-Gene Interactions. Pharmaceutics. 2020;12(12). doi:10.3390/pharmaceutics12121200

**Rüdesheim 2025** Rüdesheim S, Loer HLH, Feick D, et al. A Comprehensive CYP2D6 Drug-Drug-Gene Interaction Network for Application in Precision Dosing and Drug Development. Clin Pharmacol Ther. 2025;117(6):1718-1731. doi:10.1002/cpt.3604

**Sager 2014** Sager JE, Lutz JD, Foti RS, Davis C, Kunze KL, Isoherranen N. Fluoxetine- and norfluoxetine-mediated complex drug-drug interactions: in vitro to in vivo correlation of effects on CYP2D6, CYP2C19, and CYP3A4. Clin Pharmacol Ther. 2014;95(6):653-662. doi:10.1038/clpt.2014.50

**Schadel 1995** Schadel M, Wu D, Otton SV, Kalow W, Sellers EM. Pharmacokinetics of dextromethorphan and metabolites in humans: influence of the CYP2D6 phenotype and quinidine inhibition. J Clin Psychopharmacol. 1995;15(4):263-269. doi:10.1097/00004714-199508000-00005

**Schlender 2016** Schlender JF, Meyer M, Thelen K, Krauss M, Willmann S, Eissing T, Jaehde U. Development of a Whole-Body Physiologically Based Pharmacokinetic Approach to Assess the Pharmacokinetics of Drugs in Elderly Individuals. Clin Pharmacokinet. 2016 Dec;55(12):1573-1589. 

**Schmitt 2008** Schmitt W. General approach for the calculation of tissue to plasma partition coefficients. Toxicol In Vitro. 2008;22(2):457-467. doi:10.1016/j.tiv.2007.09.010

**Spaggiari 2014** Spaggiari D, Mehl F, Desfontaine V, et al. Comparison of liquid chromatography and supercritical fluid chromatography coupled to compact single quadrupole mass spectrometer for targeted in vitro  metabolism assay. J Chromatogr A. 2014;1371:244-256. doi:10.1016/j.chroma.2014.10.055

**Stage 2018** Stage TB, Graff M, Wong S, et al. Dicloxacillin induces CYP2C19, CYP2C9 and CYP3A4 in vivo and in vitro. Br J Clin Pharmacol. 2018;84(3):510-519. doi:10.1111/bcp.13467

**Storelli 2018** Storelli F, Matthey A, Lenglet S, Thomas A, Desmeules J, Daali Y. Impact of CYP2D6 Functional Allelic Variations on Phenoconversion and Drug-Drug Interactions. Clin Pharmacol Ther. 2018;104(1):148-157. doi:10.1002/cpt.889

**Tennezé 1999** Tennezé L, Verstuyft C, Becquemont L, Poirier JM, Wilkinson GR, Funck-Brentano C. Assessment of CYP2D6 and CYP2C19 activity in vivo in humans: a cocktail study with dextromethorphan and chloroguanide alone and in combination. Clin Pharmacol Ther. 1999;66(6):582-588. doi:10.1053/cp.1999.v66.103401001

**Thelen 2011** Thelen K, Coboeken K, Willmann S, Burghaus R, Dressman JB, Lippert J. Evolution of a detailed physiological model to simulate the gastrointestinal transit and absorption process in humans, part 1: oral solutions. J Pharm Sci. 2011;100(12):5324-5345. doi:10.1002/jps.22726

**Watanabe 2018** Watanabe R, Esaki T, Kawashima H, et al. Predicting Fraction Unbound in Human Plasma from Chemical Structure: Improved Accuracy in the Low Value Ranges. Mol Pharm. 2018;15(11):5302-5311. doi:10.1021/acs.molpharmaceut.8b00785

**Wishart 2018** Wishart DS, Feunang YD, Marcu A, et al. HMDB 4.0: the human metabolome database for 2018. Nucleic Acids Res. 2018;46(D1):D608-D617. doi:10.1093/nar/gkx1089

**Yamazaki 2017** Yamazaki T, Desai A, Goldwater R, et al. Pharmacokinetic Effects of Isavuconazole Coadministration With the Cytochrome P450 Enzyme Substrates Bupropion, Repaglinide, Caffeine, Dextromethorphan, and  Methadone in Healthy Subjects. Clin Pharmacol Drug Dev. 2017;6(1):54-65. doi:10.1002/cpdd.281

**Zawertailo 2010** Zawertailo LA, Tyndale RF, Busto U, Sellers EM. Effect of metabolic blockade on the psychoactive effects of dextromethorphan. Hum Psychopharmacol. 2010;25(1):71-79. doi:10.1002/hup.1086
 







